Damianou, Christakis A. (rp03998)
- Contact Information
- Honours/Awards List
- Bibliometrics
- Publications
- Teaching List
- Supervisor Undergraduate projects
- Supervisor Phd/Msc Projects
- Projects
- Creative Works
- Patents
- Performances
- Research Contribution in Events
- University Contribution in Events
- Networking
- Invitation as guest/keynote speaker
- Commitee Membership
- External Commitee Membership
- Other Services
- Review Activity
- Training Activity
- Participation in Association
- Participation in Editorial Board
- Biography
Damianou, Christakis A.
Δαμιανού, Χριστάκης Α.
Christakis Damianou received a B.Sc., M.Sc., and Ph.D. from the University of Arizona in Electrical engineering in 1988, 1990 and 1993 respectively. He was employed at the universities of Arizona, Indiana, Harvard and Frederick. Since he returned to Cyprus (1995) his goal was to create a competitive laboratory in MRI guided focused ultrasound surgery. Christakis Damianou is currently associate professor at Cyprus University of Technology with the Electrical engineering department (since September of 2012). He teaches courses in the area of biomedical engineering (bioengineering, medical imaging and medical electronics). His research interests include MRI guided therapeutic ultrasound and MRI compatible robotics. So far he was involved in 22 research programs, having the coordination of 9 of them. The acronyms of the main programs that he participated are: ULTRASOUND Ι, ULTRASOUND II, SONOTHERM, ODISEAME, NETTLE, N2L, SONOMRI, BRAINSONIC, SONOSTROKE, PROFUS, SONOPLAQUE and ULTRASTROKE. Based on his research activities he published 81 scientific papers and 3 book chapters. He is the inventor of an international patent: ‘MRI positioning system for ultrasound brain surgery’ (WO/2007/082495). Since 1990 he is involved in the area of MRI guided Focused Ultrasound (MRgFUS) for medical applications. He is the co-inventor of MRgFUS which is a technology with many medical products globally. Intense ultrasound causes high temperatures (60-100 oC). Therefore this modality can be used to destroy cancer cells. This technology is focused and therefore only a specific target is destroyed, leaving the surrounding tissue unaffected. This technology was never commercialised in the past because there was no effective imaging method to monitor the therapy. Recently with the utilization of MRI, the heating due to ultrasound can be reliably monitored. The technology of MRgFUS is considered the best ablating modality of deep-seated targets and therefore is becoming an effective and attractive engineering-based surgical procedure.